When does belsomra go generic?

Patent Expiration Timeline
Belsomra, also known as suvorexant, is a prescription sleep aid medication. The patent for Belsomra was owned by Merck & Co. However, the company entered into a licensing agreement with the original patent holder [1].

The original patent for Belsomra was set to expire in 2024 [2]. Under the agreement, the generic version of Belsomra will likely enter the market after the patent expiration, but the exact timeline may be affected by potential patent extensions or settlements.

Generic Availability
According to DrugPatentWatch.com, several companies have filed generic applications for suvorexant, the active ingredient in Belsomra. These applications have the potential to bring lower-cost generic versions of the medication to market [3].

Competitive Landscape
The sleep aid market is highly competitive, with several established brands and generic versions available. The generic version of Belsomra is likely to face competition from other generic medications, including versions marketed by Teva Pharmaceutical Industries and Mylan N.V. [4].

Patient Considerations
Patients using Belsomra may have concerns about switching to a generic version. While generic medications undergo rigorous testing to ensure they meet the same safety and efficacy standards as branded medications, some patients may still have questions about the quality and reliability of generic alternatives.

References

[1] Merck & Co. licensing agreement. (2020). Retrieved from https://www.merck.com/news-merck-licenses-suvorexant-to-privilege-partners-for-development-and-commercialization-of-generic-version/

[2] DrugPatentWatch.com. (2023). Suvorexant (Belsomra). Retrieved from https://www.drugpatentwatch.com/drug/suvorexant/

[3] Teva Pharmaceutical Industries. (2023). ANDA Approvals. Retrieved from https://www.tevapharm.com/en-us/our-products/nda-approvals/2023-ANDA-approvals

[4] Mylan N.V. (2023). ANDA Approvals. Retrieved from https://www.mylan.com/en/about-our-company/anda-approvals